The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines - PubMed (original) (raw)
. 2018 May;58(3):219-225.
doi: 10.1016/j.scijus.2017.12.004. Epub 2017 Dec 22.
Affiliations
- PMID: 29685303
- DOI: 10.1016/j.scijus.2017.12.004
The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines
Laura Waters et al. Sci Justice. 2018 May.
Abstract
The illicit market for new psychoactive substances is forever expanding. Benzodiazepines and their derivatives are one of a number of groups of these substances and thus far their number has grown year upon year. For both forensic and clinical purposes it is important to be able to rapidly understand these emerging substances. However as a consequence of the illicit nature of these compounds, there is a deficiency in the pharmacological data available for these 'new' benzodiazepines. In order to further understand the pharmacology of 'new' benzodiazepines we utilised a quantitative structure-activity relationship (QSAR) approach. A set of 69 benzodiazepine-based compounds was analysed to develop a QSAR training set with respect to published binding values to GABAA receptors. The QSAR model returned an R2 value of 0.90. The most influential factors were found to be the positioning of two H-bond acceptors, two aromatic rings and a hydrophobic group. A test set of nine random compounds was then selected for internal validation to determine the predictive ability of the model and gave an R2 value of 0.86 when comparing the binding values with their experimental data. The QSAR model was then used to predict the binding for 22 benzodiazepines that are classed as new psychoactive substances. This model will allow rapid prediction of the binding activity of emerging benzodiazepines in a rapid and economic way, compared with lengthy and expensive in vitro/in vivo analysis. This will enable forensic chemists and toxicologists to better understand both recently developed compounds and prediction of substances likely to emerge in the future.
Keywords: Benzodiazepines; Biological activity; GABA(A) receptor; New psychoactive substances; Prediction; QSAR.
Copyright © 2017 The Chartered Society of Forensic Sciences. Published by Elsevier B.V. All rights reserved.
Similar articles
- Development of QSAR model based on Monte Carlo optimization for predicting GABAA receptor binding of newly emerging benzodiazepines.
Antović A, Karadžić R, Živković J, Veselinovic A. Antović A, et al. Acta Chim Slov. 2023 Nov 23;70(4):634-641. doi: 10.17344/acsi.2023.8465. Acta Chim Slov. 2023. PMID: 38124634 - Pharmacophore, 3D-QSAR, and Bayesian model analysis for ligands binding at the benzodiazepine site of GABAA receptors: the key roles of amino group and hydrophobic sites.
Yang Y, Zhang W, Cheng J, Tang Y, Peng Y, Li Z. Yang Y, et al. Chem Biol Drug Des. 2013 May;81(5):583-90. doi: 10.1111/cbdd.12100. Epub 2013 Mar 26. Chem Biol Drug Des. 2013. PMID: 23279907 - Comparative quantitative structure-activity relationship studies (QSAR) on non-benzodiazepine compounds binding to benzodiazepine receptor (BzR).
Hadjipavlou-Litina D, Garg R, Hansch C. Hadjipavlou-Litina D, et al. Chem Rev. 2004 Sep;104(9):3751-94. doi: 10.1021/cr0304469. Chem Rev. 2004. PMID: 15352779 Review. No abstract available. - Pharmacology of benzodiazepine receptors: an update.
Sieghart W. Sieghart W. J Psychiatry Neurosci. 1994 Jan;19(1):24-9. J Psychiatry Neurosci. 1994. PMID: 8148363 Free PMC article. Review.
Cited by
- The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines.
Manchester KR, Waters L, Haider S, Maskell PD. Manchester KR, et al. Forensic Toxicol. 2022 Jul;40(2):349-356. doi: 10.1007/s11419-022-00616-y. Epub 2022 Mar 16. Forensic Toxicol. 2022. PMID: 36454409 Free PMC article. - Notes from the Field: Illicit Benzodiazepines Detected in Patients Evaluated in Emergency Departments for Suspected Opioid Overdose - Four States, October 6, 2020-March 9, 2021.
Aldy K, Mustaquim D, Campleman S, Meyn A, Abston S, Krotulski A, Logan B, Gladden MR, Hughes A, Amaducci A, Shulman J, Schwarz E, Wax P, Brent J, Manini A; Toxicology Investigators Consortium Fentalog Study Group. Aldy K, et al. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1177-1179. doi: 10.15585/mmwr.mm7034a4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34437520 Free PMC article. No abstract available. - New psychoactive substances: a review and updates.
Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK. Shafi A, et al. Ther Adv Psychopharmacol. 2020 Dec 17;10:2045125320967197. doi: 10.1177/2045125320967197. eCollection 2020. Ther Adv Psychopharmacol. 2020. PMID: 33414905 Free PMC article. Review. - Designer drugs: mechanism of action and adverse effects.
Luethi D, Liechti ME. Luethi D, et al. Arch Toxicol. 2020 Apr;94(4):1085-1133. doi: 10.1007/s00204-020-02693-7. Epub 2020 Apr 6. Arch Toxicol. 2020. PMID: 32249347 Free PMC article. Review. - A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues.
Giorgetti A, Sommer MJ, Wilde M, Perdekamp MG, Auwärter V. Giorgetti A, et al. Forensic Toxicol. 2022 Jan;40(1):180-188. doi: 10.1007/s11419-021-00591-w. Epub 2021 Aug 11. Forensic Toxicol. 2022. PMID: 36454486 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources